Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more

Hematology Education & Training

The European Hematology Association (EHA) is the largest provider of independent, evidence-based, and peer-reviewed medical and scientific education in hematology in Europe.

Read more

YoungEHA

Welcome to YoungEHA!As a junior member of EHA, you are part of the YoungEHA family.

Read more

Jobs at EHA

The European Hematology Association (EHA) is a not-for-profit organization that supports and connects hematologists worldwide. EHA promotes excellence in patient care, research, and education in hematology towards a cure for all blood disorders.

Read more

Research trainings

Old ways won't open new doors. Via non-pecuniary awards, EHA strives to accelerate the careers of promising post-docs in translational or clinical research.

Read more

EU Elections and Health Policy

HemAffairs Article #1 – June 2019

2019 will see significant changes within the European institutions.

Read more